332-333 / 2953
IMRT prospective clinical trials 2
Preoperative IGRT 50Gy in 25 fractions prior to surgery
IGRT used in order to reduce target volumes
Primary endpoint: 15% absolute improvement in rate of grade ≥2
radiation morbidity (subcutaneous tissue fibrosis, joint stiffness,
oedema) at 2 years, from 37% to 22%
79 patients (2008 – 2010)
Could receive IMRT (74.7%) or 3DCRT (25.3%)
Results:
5/74 (7%) local recurrences (all in field)
57 patients assessed for late toxicity – 10.5% experienced at
least one grade ≥2 toxicity (vs 37% in SR2 trial) p<0.001
Conclusion: The significant reduction in late toxicities, and absence
of marginal recurrences suggest that the reduced volumes used
were appropriate
30
Wang et al Journal of Clinical Oncology 2015 Jul 10;33(20):2231-8. doi:
10.1200/JCO.2014.58.5828. Epub 2015 Feb 9.